BackEucrates Biomedical Acquisition - Warrants (23/10/2027) Overview

Eucrates Biomedical Acquisition - Warrants (23/10/2027) Total Assets

Latest total assets for EUCRW: $12M.

Get informed when a big investor buys or sells

+ Follow
Total Assets
$12.49M
88.12% YoYΔ $-92.62M vs prior year quarter

Peer average

Loading

Eucrates Biomedical Acquisition - Warrants (23/10/2027) Total Assets History

Loading

Eucrates Biomedical Acquisition - Warrants (23/10/2027) vs. peers: Total Assets Comparison

Loading

Eucrates Biomedical Acquisition - Warrants (23/10/2027) Total Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Eucrates Biomedical Acquisition - Warrants (23/10/2027) (EUCRW) FAQ

Eucrates Biomedical Acquisition - Warrants (23/10/2027) (EUCRW) currently reports a total assets of $12M as of December 2022. That compares with $110M in the prior-year period — down 88.1% year over year. Use the charts on this page to explore Eucrates Biomedical Acquisition - Warrants (23/10/2027)'s total assets history and peer comparisons.

Eucrates Biomedical Acquisition - Warrants (23/10/2027)'s total assets decreased from $110M to $12M — a 88.1% year-over-year decrease (period ending December 2022). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Eucrates Biomedical Acquisition - Warrants (23/10/2027) reported $12M in total assets as of December 2022. That compares with $110M in the prior-year period — down 88.1% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total assets of $12M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Eucrates Biomedical Acquisition - Warrants (23/10/2027), and consider following EUCRW for alerts when major investors trade the stock.